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Metalioprotemases ,ld their specific mhibltors, believed to play a role in extraeellular matrix metabolism, are regulated by inflammatory cytokmes. 
Here we have addressed the question of whether liver, the major site of ~yntltests of plasma pl'oteinase mh~b~tors, is al~o capable ,~f synthesxzing 
the tissue inhibitor of metalloprotentase-I (TIMP.I) We show at mRNA and protein levels that TIMP-I 15 expres~d in differentiated human 
hepatoma cells (HepG2) and that its syntltesi.~ s up-regulated by interleakin-6 (IL-6), transforming growth factor ,81 and phorbol 12-mynstate 
13-acetate. The physiological role of this phenomenon is underhned bythe fact hat hpopoly~aeehartde dmmistmtmn into rat~ in vlvo. a~ well 
as IL-6-stmmlation f mt hepatocytes in primary culture, also leads to an merea~e ofTIMP-I mRNA in liver cells 
Tissue inhibitor of mctalloproteinase- 1 (TIMP-I), Metalloprotemase, lnterleukm-6 (I L-6); Translbrmmg growth factor fll (TGF~I); Hepatoma 
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1. INTRODUCTION 
Recently much attention has been paid to proteinases 
and their iahibitors involved in tissue remodelling. Par- 
ticularly, several metalloproteinases have been shown to 
play a role in the degradation and turnover of  the ex- 
traeellular matrix composed of collagens, proteogly- 
cans, and glyeoproteins like fibronectin and laminin. 
The metalloproteinases aresynthesized and secreted as 
inactive precursors and their activity in the extracellular 
milieu is regulated by inhibitors. The major inhibitors 
of metalloproteinases areat2-macroglobulin a d tissue 
inhibitors of metalloproteinases (TIMP- 1 and TIMP-2) 
(reviewed in [1-4]). T!MP-I is a glyeoprotein with a 
molecular mass of about 29 kDa mainly produced by 
cells of mesodermal origin [3]. 
Thus far, TIMP-1 synthesis has been described as 
being regulated by growth factors and eytokines uch 
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as epidermal growth factor (EGF), basic fibroblast 
growth factor (bFGF), transforming growth factor-ill 
(TGFfll), interleukin-! (IL-D and tumor necrosis fac- 
tor-g TNFR [5-91. Recently° IL-6 has been shown to 
stimulate TIMP-I expression in human ehondrocytes, 
fibroblasts and synoviocytes [10,11]. it has also been 
reported that TIMP-1 is present in serum of normal 
individuals [12,13]. 
Since liver is the major site of synthesis of plasma 
proteinase inhibitors, we asked whether hepatocytes 
al~o synthesize TIMP-I and whether this expression is
regulated by ¢ytokines. As a model system for human 
hepatocytes, we used the human hepatoma cell line, 
HepG2, which has been shown to be capable of synthe- 
sizing and secreting essentially the whole spectrum of 
human acute-phase proteins [14]. Here, we describe for 
the first time that HepG2 cells synthesize and secrete 
TIMP-I. We also present data on tile up-regulation of 
TIMP-I by IL-6, TGFfll and phorbol 12 myristate 13- 
acetate (PMA). Furthermore, we show that TIMP-I 
mRNA increases in livers of lipopolysaccharide (LPS)- 
treated rats, as well as in rat hepatocytes in primary 
culture after stimulation with IL-6. 
2. MATERIALS AND METHODS 
2.1 Chemicals 
Restrieuon enzymes and random primed DNA labelling kit were 
Pubhshed by Elsevier Science Pubhshers B V. 143 
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purchased from Boehrtnger-Mannhe,m (Mannhema. Germany) 
[g-~-'P]dATP (110 TBq/mmol) was obtained from Amer~ham Inter na- 
tional (Ainu, sham, UK). DMEM and DMEM/FI2 wa~ from G,beo 
(Eggenstem, Germany) Eschertchta coh LPS was flora S~gma (Mu- 
md~, Germany) Human TOF/~I wa~ purchased from B,ermann (Bad 
Nauheim, GcHnany). Planm,d pTrPCi9 containing human I"IMP-I 
eDNA was kindly provided by Dr. M Nature (Toray lndastr,es Inc., 
Japan). A I kb £coRl fiagment wa~ u~cd for labehng. Plasmid 
pBSmTIMP-I containing mou~e TIMP-I eDNA was a gift from Dr 
D.R. Edward~ (Umvelsity of Calgary, Canada) For hybud,zatton a 
825 bp Htndlll-B#mHi fia~ment wan u~ed. The plasmid pACT con- 
tamm~ human ct~-antiehymotiypsm (a~ACq') eDNA was a gift from 
Dr E Burger (University of Zurich, Switzerland). Foi hybridization 
a 1.5 kb Pstl fragment w,t~ uncd. Recombinant human IL-6 (rhlL-6) 
was prepared by J Mtlllberg using a T7 eDNA expression system. 
o° .,, 
T IMP =1 
2.2. ,.lnmtal~ attd cuff ctthure 
Male Sprague-Dawley rat~ of 200-300 g body weight we,e injected 
mtrapentoneally with 10 mg LPS per kg body we,ght After the times 
indicated the animals were kdled by a~phyxmt,on a d the hvets we]e 
removed immedi,it¢ly. 
HepG2 cell~ were obtained from the American Type Culture Collec- 
tion (Rocky,lie. MD. USA) and cultured m DMEM/DMEM-FI2 
medium ~upplemented with 10% FCS, ~treptomyeha (100 me,/l) and 
pemelllin (61 regal) 
Primary rat hepatocytes were prepared by peffu~,on of the hver as 
described [15]. Hepatocyte~ were cultured in M 199 medium ~upple- 
rnented w,th 4% FCS, streptomycin (100 rng/l), pemelllm (61 rag/I). 
denamethasone (10 -~ M) and m~uhn t5 10-"'). 
2.3 RNA prepat'atton and Northertl blot attalvsts' 
Total RNA was prepared using the phenol extraction method a.~ 
described m [16,17] 5 gg of RNA weir heated to 65°C for 10 mm tn 
50% form,tin,de, 20 mM morphohnopropane sulphonic ac,d (MOPS), 
5 mM ~od, um acetate, 1mM EDTA, 2.2 M fo, maldehydc prior to gel 
electrophore~,~ m I% agarose containing 2.2 M formaldehyde. 20 mM 
MOPS. 5 mM sodium acetate and 1 mM EDTA Equal loading of the 
RNA 8el was cl~¢cked by ethidium bromide staining of 18 S and 28 
S ribosomal RNA The separated RNA was tranbferred to Gene- 
Screen Plu~ membranes (DuPont-DeNemours. Dre,e,ch, Germany) 
according to the ~upplier's instruetien~. The fil~er~ sere p:ehybridized 
at 68°C for 3 h m 10% dextrtin sulfate, 1 M sodium chloride, 1% SDS. 
and hybridized in the ~ame soluuon wah eDNA fragment~ hibelled by 
random priming [18]. After hybridization, non-specifically bound ra- 
dioaetiv,ty was removed by w-tshmg m 2× ~tandard ~ahne ~oluuon 
(SSC) at room temperature, followed by two ~ub~equent wa~he~ m 2 
× SSC/1% SDS at 68°C for 30 min each. The filters were then subjected 
to autorad,ography using intensifying screens. 
2.4. Metabolic labellh~g oJ HepG2 cell.~ and hnmunopt ecq)itat/on 
HepG2 cell~ were grown to eonflueney on 35-ram plast,c dishes and 
numulated for 18 h with lk-6 (100 U/ml). TGF/~I (5 n~/ml) or PMA 
(10 -~ M) Cell~ were washed with pllo~phate-buffe,ed sal,ne and incu- 
bated foi 3 h with 150 :tl [s~S]methionme/eysteme (Tran'SS-label, ICN. 
Mcckenheim, Germany) in 5003tl of methionine/eysteine-free D M EM 
containing 0.2% bovine serum albumin and 10 mM Hepes, pH "/.3. 
Aller addit,on of 10 × the no,anal concentration of meth,onme/cyste- 
ine, cell~ were further incubated for 2 h at 37°C. 
Medium was removed and centrifuged for 5 mm m a mierofuge Tile 
supernatant wtm adjusted to 1% Triton X-100 and 0 1% SDS and 
preincubated with Pansorbin (Calbioehem, Frankfurt, Or, many) 1"61 
1 h at 4°C. After eentrifugauon for 5 ram, the supematant was re- 
moved and lmmunopreuipitated with a polyclonal rabb, t antiserum 
raised against human TIMP-I followe:J by protein A-Sephalose 
(Pharmaeia. Fretburg. Germany) absorption, lmmunopree~pitate~ 
were ¢lutecl by bmlmg m SDS-PAOE ~ample buff'c, and ~ubjceted to 
12% SDS-PAGE according to Laemmh [19]. Gels were fixed and 
impregnated w,th 1 M sodmm suhcyl:,te [20] and exposed to a Cronex- 
4 (DuPont-DeNemours, Dietrich) fihn at -80°C. 
=mm,,q lp(,m,m 0[, 1 ACT 
Fig. 1. Effect of IL-6, PMA and TGFpl on mRNA level.., of TIMP-1 
and ~I-ACT. Confluent HepG2 cells in medium contamm 8 10% FCS 
weir stimulated w,th 100 BSF-2 U of IL-6 pet ml, 100 ngofPMA pc," 
ml and 4 ng of TGF,81 pel ml medium lbr 18 h. Total RNA w,,~ 
~olated aqd 5,ttg were u~ed for Northern blot analys)s ofTIMP-I and 
~ACT-mRNA. 
3, RESULTS 
HepG2 cells were incubated with rhlL-6 and the 
known stimulators of TIMP-I synthesm, TGFFll and 
PMA. mRNA levels for TIMP-I and a~ACT were de- 
termined by Northern blot analysis. Fig. 1 (upper panel) 
shows that untreated HepG2 cells constitutwely express 
TIMP-I mRNA. Upon incubation with IL-6 or 
TGFFll, TIMP-I mRNA levels increased 2-3-fold. A 
dramatic stimulation of TIMP-1 mRNA was observed 
after treatment of HepG2 cells with PMA. For compar- 
ison we have included the Northern blot for the well- 
known human acute-phase protein, ~ACT (Fig. 1, 
lower panel). As expected, ~x~ACT mRNA levels in- 
creased >5-fold and 2-3-fold upon treatment with IL-6 
or TGF'Fll, respectively. In contrast to TIMP-I, concen- 
trations of c~ACT mRNA were slightly reduced after 
PMA. The dose- and time-dependence of TIMP-1 
mRNA induction by IL-6 is shown in Fig. 2. A slit~ht 
reduction was already observed at an IL-6 concentra- 
tion of 10 U/ml, maximal TIMP-1 mRNA levels were 
achieved at 50 U/ml el IL-6 (Fig. 2A). TIMP-1 mRNA 
was fully induced 4 h after incubation with II,-6 (Fig. 
2B). 
In order to demonstrate TIMP-I synthesis and regu- 
!atio,~- by !L-6, TGFFl! and PM.A also at the protein 
level, we have metabolically labelled HepG2 cells with 
[~S]methionine/[s~S]cysteine for 3 h and imnaunoprecip- 
itated the newly synthesized and secreted TIMP-1 from 
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Fig. 2 Dose- and time.dependence of TIMP-I mR.NA induction by 
IL-6. Confluent HepG2 ~.ells in medlt,m containing 10,% FCS were 
stimulated with increasing amounts of IL-6 (A) or with 100 BSF-2 U 
of human recombinant IL-6 per ml for the times indicated in B. As 
described in the legend to Fig. 1, total RNA was isolated and ,ised for 
Northern blot analysm. 
the media. Fig. 3 shows that TIMP-I protein is constitu- 
tively produced by HepG2 cells and up-regulated by 
IL-6, TGFfll and PMA. Specificity of the immunopre- 
cipitated protein at a mobility corresponding to an ap- 
parent molecular mass of 29 kDa was confirmed by 
competition studies with purified unlabelled TIMP-1 
(not shown). The band on top of the gel represents high 
molecular weight material (non-specifically bound to 
the antibody upon immunoprecipitation since it could 
not be competed out with an excess of unlabelled TIMP- 
1. We also examined TIMP-I expression i  rat liver in 
vivo and in rat hepatocytes in vitro. LPS was injected 
intraperitoneally into male rats. Such an experimental 
approach as been widely used to mimic inflammatory 
conditions because it leads to the secretion of inflamma- 
tory cytokines uch as IL-I, TNFcx and IL-6 by mon- 
ocytes [21]. Total RNA was isolated from livers alter 24 
h and subjected to Northern blot analysis. It is evident 
from Fig. 4A that LPS administration strongly induced 
TIMP-1 mRNA expression i rat liver. An induction of 
TIMP-1 mRNA was also found in rat hepatocytes in 
primary culture after stimulation with IL-6 (Fig. 4B). 
4. DISCUSSION 
We have shown in the present study that T1MP-I is 
constitutively synthesized and secreted by human 
hepatoma ceils (HepG2). Our major finding is the stim- 
ulation of TIMP-I synthesis by IL-6 in hepatic ells. 
IL-6 is characterized bya pleiotropie spectrum of action 
[22,23]. Besides its functiori n the immune system and 
during hematopoiesis, IL-6 has been shown to be a 
major regulator of acute-phase protein synthesis n liver 
cells [24-29], Most of the acute-phase proteins which 
are induced by IL-6 in hepatic ells are proteinase inhib- 
itors such as cq-antitrypsin, cx~-ACT, cq-macroglobulia 
and Cl-inhibitor [21,30,31]. Except for ot2-macroglob- 
ulin [1], none of these inhibitors is capable of inhibiting 
metalloproteinases. Metalloproteinases r leased uring 
Mr, lO  "a 
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Fig. 3. Stimulation of TIMP-I ~ynthesis by IL-6, TGFfll and PMA. 
Confluent HepG2 cells in medi-m containing 10% FCS were stlmn- 
lated w~th 100 BSF-2 U of human IL-6 per ml, with 2 ng of human 
TGFfll per ml, or 100 ng of FMA per ml of medium for 18 h. 
Subbequently, t:ells were labelled with [3~Slmethiomned[~S]eysteine as 
described in ~eeuon 2. Radioactwely labelled TIMP-I was im- 
munopreeipit,'tted from lhe ~upernatants with a polyclonal antiaerum 
to human TIMP-I. The lmmunopreeipitated TIMP-l/antibody com- 
plexes were sub i~ted to SDS-PAGE and fluororadiogniph2¢. 
tissue injury or mflammatory processes from mon- 
oeytes, macrophages, neutrophils, fibroblasts or endo- 
thelial cells need to be controlled by specific inhibitors 
to prevent damage of extracellular matrix of healthy 
tissue [1]. TIMP-I and TIMP-2 have been found and 
characterized as highly specific inhibitors of metal- 
loproteinases [12,32]. Thus far, IL-6 stimulation of 
"liMP-1 expression has only been shown in hbroblasts, 
synovioeytes and chondrocytes [10,11]. In all three 
cases, the stimulation was performed under low serum 
(<1%) conditions. In the presence of 10% FCS, we could 
not induce TIMP-1 synthesis in human chondroeytes 
by IL-6 (Graeve t al., unpublished work). However, in 
HepG2 cells TIMP-1 up-regulation by IL-6 was ob- 
served in the presence of 10% FCS. The increase in 
TIMP-1 mRNA and secreted protein after IL-6 stimula- 
tion was abol~t 2-3-fold. Comparable moderate stimu- 
latory effects were observed in various other cell lines 
and primary cuiturt~ al'u:f '- -' .... -_- ,,''rI,~AO I .. . .  *h~ Ai lULI I~t,IU I I  U I  • £,t, Y l l  - ~J .  l l t . l l ' "
sis by 1L-l/S, TGF/$1, bFGF, EGF, TNFa and LPS 
[5-91. 
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Fi~. 4. Effect of LPS and 1L-6 on TIMP-1 mRNA expt~bo, ia rat liver and in rat hepatocytes in primary culture. (A) Rats were injeet~.xl 
mtrapentoneally with 10 m8 LPS per kg body weight After 24 h RNA was prepared from rat livers and subjected to Northern blot analysis using 
a eDNA probe foi mmine TIMP-1. (B) Primary rat hepatocytes were stimulated with different amounts of IL-6 for 18 h. Isolated RNA was analyzed 
by Northern blotting 
Among me various stimulators te~tcd in HepG2 cells, 
PMA exhibited by far the most dramatic induction of 
TIMP-1 mRNA. This observation has also been made 
in other systems [5,8]. The TIMP-1 gene has recently 
been cloned and its promoter characterized [33,34]. A 
PMA-responsive clement was identified. It should be 
noted that the huge increase in TIMP-1 mRNA after 
PMA stimulation was not followed by a comparable 
increase in newly synthesized TIMP-1 protein (see Fig. 
3). A similar observation has been made by other inves- 
tigators in human fibroblasts [7] and synovial cells [8]. 
Presently the nature of the physiological mediator 
whose action is mimicked by PMA is unknown. 
In addition to the results obtained with human 
hepatoma cells we performed in rive and in vitro exper- 
iments with rat hcpatocytes. A strong increase in TIMP- 
1 mRNA concentration~ was observed in rat liver after 
intraperitoneal LPS injection. This clearly shows that 
TIMP-1 expression is induced in liver under inflamma- 
tory conditions. At present we cannot rule out the pos- 
sibility that besides hepatocytes endothelial cells, 
Kupffer and lto cells which are minor cell populations 
in the liver, also contribute to this effect. Furthermore, 
additional mediators may play a role in TIMP-1 induc- 
tion in rive, particularly because LPS triggers the re- 
lease of a whole spectrum ofcytokines from monocytcs/ 
macrophages. This question is currently under investi- 
gation. However, in preliminary experiments we have 
found that IL-6 stimulated TIMP-1 expression in rat 
hepatocytes (see Fig. 4B). In conclusion we propose 
TIMP-1 to be an acute-phase reactant inducible by IL-6 
in vitro and by LPS in vivo. 
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